Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Long-Term Investments: 2021-2025

Historic Long-Term Investments for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Sep 2025 value amounting to $67.2 million.

  • 4D Molecular Therapeutics' Long-Term Investments rose 37.69% to $67.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 37.69%. This contributed to the annual value of $80.6 million for FY2024, which is 635.65% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Long-Term Investments is $67.2 million, which was down 45.75% from $123.8 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Long-Term Investments high stood at $137.0 million for Q1 2025, and its period low was $1.4 million during Q1 2023.
  • In the last 3 years, 4D Molecular Therapeutics' Long-Term Investments had a median value of $62.9 million in 2024 and averaged $63.2 million.
  • In the last 5 years, 4D Molecular Therapeutics' Long-Term Investments slumped by 97.09% in 2023 and then soared by 4,379.86% in 2024.
  • 4D Molecular Therapeutics' Long-Term Investments (Quarterly) stood at $67.7 million in 2021, then slumped by 92.75% to $4.9 million in 2022, then soared by 123.19% to $11.0 million in 2023, then soared by 635.65% to $80.6 million in 2024, then skyrocketed by 37.69% to $67.2 million in 2025.
  • Its Long-Term Investments was $67.2 million in Q3 2025, compared to $123.8 million in Q2 2025 and $137.0 million in Q1 2025.